Patents by Inventor Herwig Brunner

Herwig Brunner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20040182791
    Abstract: The invention relates to an efficient process and device for the decontamination of waters polluted with heavy metals, semimetals and/or radionuclides by cation exchange and electrochemical deposition of the anions.
    Type: Application
    Filed: October 30, 2002
    Publication date: September 23, 2004
    Inventors: Manfred Kuhn, Herwig Brunner, Andreas Wolf, Gunther Mann
  • Patent number: 6770455
    Abstract: The present invention relates to metal-containing ribonucleotide polypeptides (RNP) and processes for their production, their use and medicaments containing ribonucleotide polypeptides or their molecular-biological equivalent structures and/or parts and/or derivatives.
    Type: Grant
    Filed: January 16, 2001
    Date of Patent: August 3, 2004
    Assignee: Fraunhofer
    Inventors: Stefan Kiesewetter, Eckehard Kuhn, Bridgitte Koch-Pelster, Herwig Brunner
  • Publication number: 20040116337
    Abstract: The invention concerns a peptide having the biological activity of an inhibitor of amyloid formation and its diagnostic and medical use.
    Type: Application
    Filed: January 14, 2004
    Publication date: June 17, 2004
    Inventors: Afroditi Kapurniotu, Jurgen Bernhagen, Herwig Brunner
  • Patent number: 6699698
    Abstract: The present invention relates to a method and an apparatus for separating substances from or in biological materials.
    Type: Grant
    Filed: December 22, 2001
    Date of Patent: March 2, 2004
    Assignee: Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V.
    Inventors: Frank Vitzthum, Jürgen Bernhagen, Elkin Bentsian, Herwig Brunner, Georg Geiger
  • Patent number: 6617423
    Abstract: Calcitonins and calcitonin derivatives such as are employed for therapy for, for example, osteoporosis. Paget's disease or hypercalcemia. The calcitonins and calcitonin derivatives are distinguished by a bridging of the amino acids present in the positions 17 and 21. In this case, by means of a suitable choice of the amino acids present in these positions an 18- or 19-membered ring is produced. This ring leads to an increased conformational stability and to an increased activity of the modified calcitonin. A particularly suitable hCt (human Ct) analog is the cyclo17,21-[Asp17, Orn21]-hCt according to the invention having a 19-membered ring structure between the lactam-bridged Asp17 and Orn21.
    Type: Grant
    Filed: December 20, 2000
    Date of Patent: September 9, 2003
    Assignee: Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung E.V.
    Inventors: Afroditi Kapurniotu, Jurgen Bernhagen, Herwig Brunner
  • Patent number: 6511831
    Abstract: The invention relates to a method and a device for the isolation and purification of nucleic acids. According to the invention, after decomposition of a sample the nucleic acids present in said sample are isolated and purified.
    Type: Grant
    Filed: December 19, 2000
    Date of Patent: January 28, 2003
    Assignee: Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung E.V.
    Inventors: Jürgen Bernhagen, Herwig Brunner, Frank Vitzthum, Bentsian Elkine, Georg Geiger, G{umlaut over (u )}nter Tovar
  • Patent number: 6433868
    Abstract: The patent relates to a method for spectroscopic and spectrofluorimetric determination of the interaction between materials. The determination takes place using apparatus consisting of several basins.
    Type: Grant
    Filed: December 30, 2000
    Date of Patent: August 13, 2002
    Assignee: Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung E.V.
    Inventors: Herwig Brunner, Jürgen Bernhagen, Frank Vitzthum
  • Patent number: 6359112
    Abstract: Certain peptide molecules can be used as the basic structures (template molecules) for inhibiting and analysing amyloid formation and cytotoxicity in amyloid illnesses. These peptides have an effect on the molecules which are responsible for the amyloid illnesses (for their part amyloid-forming peptides and proteins). The peptides are thus either inhibitors themselves or agonists of amyloid formation and cytotoxicity or can serve as a template for identifying and producing further inhibitors and agonists and can be used as molecular tools during analysis.
    Type: Grant
    Filed: June 12, 1998
    Date of Patent: March 19, 2002
    Assignee: Fraunhofer-Gesellschaft zur Forferung der angewandten Forschung e.V.
    Inventors: Afroditi Kapurniotu, Jürgen Bernhagen, Herwig Brunner
  • Patent number: 6265534
    Abstract: Superpotent calcitonin analogs have greatly increased hypocalcemic action in vivo. These calcitonins and calcitonin derivatives are employed for the therapy of, for example, osteoporosis, Paget's disease or hypercalcemia. The calcitonins and calcitonin derivatives are distinguished by a bridging of the amino acids present in the positions 17 and 21. By means of suitable choice of the amino acids present in these positions an 18-membered or 19-membered ring is produced. This ring leads to an increased conformational stability and to an increased activity of the modified calcitonin. A particularly suitable hCt (human calcitonin analog) is a cyclo17,21-[Asp17, Orn21]-hCt having a 19-membered ring structure between the lactam-bridged Asp17 and Orn21.
    Type: Grant
    Filed: August 20, 1998
    Date of Patent: July 24, 2001
    Assignee: Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung E.V.
    Inventors: Afroditi Kapurniotu, Jurgen Bernhagen, Herwig Brunner
  • Patent number: 5169758
    Abstract: The present invention provides a stabilized, NAD(P)H-dependent, soluble nitrate reductase of the assimilatory type, characterized by a molecular weight of about 90,000 D in the case of electrophoresis in the presence of sodium dodecyl sulphate and a residual activity after 3 weeks at 35.degree. C. of more than 60%, obtainable by preparing a suspension of the comminuted starting material in tris/tartaric acid buffer (pH 7-8.5), adding soluble polyethyleneimine thereto in such an amount that 10 to 20% of the nitrate reductase activity passes into the precipitation obtained, separating off the precipitate and working up the supernatant according to conventional biochemical methods of fractionation in the above-mentioned digestion buffer, dialyzing the enzyme solution obtained and lyophilizing in a zwitterionic buffer.
    Type: Grant
    Filed: August 1, 1990
    Date of Patent: December 8, 1992
    Assignee: Boehringer Mannheim GmbH
    Inventors: Stephan Fischer, Barbel Wurst, Hans-Otto Beutler, Georg-Burkhard Kresse, Herwig Brunner
  • Patent number: 4395489
    Abstract: Process for obtaining high yields of glycerol dehydrogenase from micro-organisms and glycerol dehydrogenase having a low K.sub.M value.
    Type: Grant
    Filed: December 19, 1980
    Date of Patent: July 26, 1983
    Assignee: Boehringer Mannheim GmbH
    Inventors: Peter Stahl, Hans Seidel, Herwig Brunner
  • Patent number: 4360596
    Abstract: The present invention provides a process for obtaining cholesterol esterase from micro-organisms of the genus Pseudomonas, wherein Pseudomonas sp. DSM 1280 or DSM 1281 is cultured in an appropriate culture medium in the presence of an inducer and the enzyme is obtained from the culture medium and/or from the cells.
    Type: Grant
    Filed: August 6, 1980
    Date of Patent: November 23, 1982
    Assignee: Boehringer Mannheim GmbH
    Inventors: Klaus Beaucamp, Michael Nelboeck, Helmgard Gauhl, Hans Seidel, Wolfgang Gruber, Herwig Brunner
  • Patent number: 4343903
    Abstract: The present invention provides a process for obtaining cholesterol esterase from micro-organisms, wherein a micro-organism capable of cholesterol esterase formation is cultured in an appropriate nutrient medium in the presence of lecithin as inducer and the enzyme is obtained from the culture medium and/or from the cells.
    Type: Grant
    Filed: August 6, 1980
    Date of Patent: August 10, 1982
    Assignee: Boehringer Mannheim GmbH
    Inventors: Klaus Beaucamp, Michael Nelboeck, Helmgard Gauhl, Hans Seidel, Wolfgang Gruber, Herwig Brunner